Author:
Sánchez Ramírez Javier, ,Morera Díaz Yanelys,Bequet-Romero Mónica,Hernández-Bernal Francisco,Selman-Housein Bernal Katty-Hind,de la Torre Santos Ana,Santiesteban Álvarez Eduardo Rafael,Martín Bauta Yenima,Bermúdez Badell Cimara H.,de la Torre Pupo Josué,Gavilondo Jorge V.,Ayala Avila Marta
Publisher
Springer Science and Business Media LLC
Reference59 articles.
1. Wentink MQ, Huijbers EJ, de Gruijl TD, Verheul HM, Olsson AK, Griffioen AW. Vaccination approach to anti-angiogenic treatment of cancer. Biochim Biophys Acta. 2015;1855(2):155–71.
2. Ferrara N. VEGF as a therapeutic target in cancer. Oncology. 2005;69 Suppl 3:11–6.
3. Morera Y, Bequet M, Ayala M, Lamdán H, Agger EM, Andersen P, Gavilondo JV. Anti-tumoral effect of active immunotherapy in C57BL/6 mice using a recombinant human VEGF protein as antigen and three chemically unrelated adjuvants. Angiogenesis. 2008;11(4):381–93.
4. Estévez F, Carr A, Solorzano L, Valiente O, Mesa C, Barroso O, Sierra GV, Fernández LE. Enhancement of the immune response to poorly immunogenic gangliosides after incorporation into very small size proteoliposomes (VSSP). Vaccine. 1999;18(1-2):190–7.
5. Morera Y, Bequet M, Ayala M, Velazco JC, Pérez PP, Alba JS, Ancízar J, Rodríguez M, Cosme K, Gavilondo JV. Immunogenicity and some safety features of a VEGF-based cancer therapeutic vaccine in rats, rabbits and non-human primates. Vaccine. 2010;28(19):3453–61.
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献